EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Safety and effectiveness of canakinumab in Japanese patients with cryopyrin-associated periodic syndrome: final results from a post-marketing surveillance in Japan

Chihiro Kato, Takayoshi Sasajima, Ryuta Nishikomori iD

Modern Rheumatology · 2026

DOI: 10.1093/mr/roaf104 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Rheumatology, 2026. Verfasst von Chihiro Kato und 2 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Pharma K.K., Tokyo, Japan. Hauptthemen laut MEDLINE: Cryopyrin-Associated Periodic Syndromes, Antibodies, Monoclonal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis Pharma AG, Basel, Switzerland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To assess the real-world safety and effectiveness of canakinumab, a monoclonal anti-interleukin-1β antibody, in patients with cryopyrin-associated periodic syndrome (CAPS) in a real-world setting in Japan.

Methods

All patients with CAPS who received canakinumab treatment after drug approval in Japan were registered in a post-marketing all-patient surveillance with 2-year observation period and a follow-up period of up to 5 years.

Results

Of 93 patients in the safety analysis set, the proportion of patients with any adverse drug reactions (ADRs) and any serious ADRs was 33.33% and 4.30%, respectively. The most common ADRs were infections and infestations (21.51%). Of 70 new and 18 continuing patients (roll-over from a previous clinical trial) in the effectiveness analysis set, the proportion of responders among new and continuing patients, who achieved both clinical and serological remissions, was 78.57% and 83.33%, respectively, at Week 24. Most responders remained without relapse after the remission until Week 104 (98.11% of new and 100% of continuing patients). Clinical symptoms related to auditory, joint, visual, renal, and central nervous system maintained or improved in the majority of patients.

Conclusions

Canakinumab was well-tolerated and effective during long-term treatment for patients with CAPS in the real-world setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cryopyrin-Associated Periodic SyndromesAntibodies, MonoclonalHumansAntibodies, Monoclonal, HumanizedMaleProduct Surveillance, PostmarketingFemaleJapanAdultTreatment OutcomeMiddle AgedAdolescentYoung AdultChildInterleukin-1betaAgedEast Asian People

Stichwörter der Autor:innen

Autoinflammatory diseasesMuckle–Wells syndromecanakinumabcryopyrin-associated periodic syndromefamilial cold autoinflammatory syndromeinterleukin-1βJapanneonatal onset multisystem inflammatory diseaseobservational studyrare diseases

Substanzen

canakinumabAntibodies, Monoclonal, HumanizedAntibodies, MonoclonalInterleukin-1beta

Autor:innen und Institutionen

  • Novartis Pharma K.K., Tokyo, Japan.
  • Department of Pediatrics and Child Health, Kurume University School of Medicine, Fukuoka, Japan.

ORCID-Profile: Ryuta Nishikomori

Förderung

  • Novartis Pharma AG, Basel, Switzerland

Zitieren

APA

Kato, C., Sasajima, T., & Nishikomori, R. (2026). Safety and effectiveness of canakinumab in Japanese patients with cryopyrin-associated periodic syndrome: final results from a post-marketing surveillance in Japan. Modern Rheumatology. https://doi.org/10.1093/mr/roaf104

Vancouver

Kato C, Sasajima T, Nishikomori R. Safety and effectiveness of canakinumab in Japanese patients with cryopyrin-associated periodic syndrome: final results from a post-marketing surveillance in Japan. Modern Rheumatology. 2026. doi:10.1093/mr/roaf104

BibTeX
@article{Kato2026,
  author = {Kato, Chihiro and Sasajima, Takayoshi and Nishikomori, Ryuta},
  title = {Safety and effectiveness of canakinumab in Japanese patients with cryopyrin-associated periodic syndrome: final results from a post-marketing surveillance in Japan},
  journal = {Modern Rheumatology},
  year = {2026},
  doi = {10.1093/mr/roaf104}
}
Kostenlos starten →